Directorate Change

Futura Medical plc (AIM: FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that Roy Davis has informed the Company of his decision to step down from his role as Non-Executive Director with effect from 20th October 2026.

Roy’s decision follows a review of his wider board commitments and the time required to fulfil them. With a number of other board responsibilities, Roy has concluded that this is the appropriate time to step down from the Futura Board. His decision is unrelated to the Company’s business, performance or prospects, and he remains strongly supportive of Futura and its current strategy.

Following Roy's departure, the Board will consist of Andrew Unitt (Chair), Alexander Duggan (Chief Executive Officer), Angela Hildreth (COO and Finance Director) and Ken James (Head of R&D). The board has given careful consideration to its composition and, given the Company's current position, the Board does not intend to appoint a replacement Non-Executive Director at this time. The Board will monitor its composition and governance requirements carefully.

Andrew Unitt, Chair of Futura, commented:

"On behalf of the Board, I would like to thank Roy for his outstanding contribution to Futura. His experience, insight and advice have been invaluable during an important period in the Company's development. While we are sorry to see him step down, we fully understand his decision as part of a long-planned review of his wider board and time commitments, and we are pleased that he remains strongly supportive of Futura."